Sign in

    Dexcom Inc (DXCM)

    You might also like

    DexCom, Inc. is a medical device company specializing in the design, development, and commercialization of continuous glucose monitoring (CGM) systems for diabetes management. The company sells integrated CGM systems, including the Dexcom G6 and G7, as well as the Stelo sensor, which is the first over-the-counter glucose biosensor in the U.S. . DexCom generates revenue from disposable sensors and reusable hardware, such as transmitters and receivers, with sales influenced by factors like seasonality and insurance deductible resets . In 2023, the company reported a significant increase in revenue, reflecting strong demand for its products .

    1. Dexcom G6 and G7 Integrated CGM Systems - Provides continuous glucose monitoring for diabetes management, used by patients, caregivers, and clinicians worldwide.
    2. Stelo Sensor - Offers a 15-day glucose monitoring solution for people with Type 2 diabetes who do not use insulin, available over-the-counter in the U.S.
    3. Disposable Sensors - Supplies sensors that are used with CGM systems, contributing to recurring revenue through regular replacements.
    4. Reusable Hardware - Includes transmitters and receivers that work with CGM systems, providing essential components for continuous glucose monitoring.
    NamePositionStart DateShort Bio
    Kevin R. SayerChairperson, President, and Chief Executive OfficerJanuary 2015Kevin R. Sayer has been serving on the Board of Dexcom since November 2007. He became the President and Chief Executive Officer in January 2015 and has been the Chairperson of the Board since July 2018. Prior to his current roles, he was the President of Dexcom starting in 2011 and served as the Chief Operating Officer from January 2013 to January 2015 .
    Jereme M. SylvainExecutive Vice President, Chief Financial OfficerMarch 2021Jereme M. Sylvain has served as the Executive Vice President and Chief Financial Officer of Dexcom since March 2021. He joined Dexcom in September 2018 as Vice President, Finance and Corporate Controller. Prior to his role as CFO, he served as Senior Vice President, Finance and Chief Accounting Officer starting in March 2020 .
    Michael J. BrownExecutive Vice President, Chief Legal OfficerJanuary 2022Michael J. Brown is the Executive Vice President and Chief Legal Officer at Dexcom, where he has worldwide responsibility for all legal and intellectual property matters. He joined Dexcom in January 2022. Before joining Dexcom, Mr. Brown was a partner at DLA Piper from January 2017 until January 2022 .
    Matthew DolanExecutive Vice President, Strategy, Corporate Development and Dexcom LabsSeptember 2022Matthew Dolan has served as the Executive Vice President of Strategy, Corporate Development & Dexcom Labs since September 2022. He joined Dexcom in 2015 and has held various positions of increasing responsibility. Before his current role, he was the Senior Vice President of Strategy, Corporate Development and New Markets from March 2021 to September 2022 .
    Teri L. LawverExecutive Vice President, Chief Commercial OfficerJanuary 2023Teri L. Lawver has served as the Executive Vice President and Chief Commercial Officer of Dexcom since January 2023. Before joining Dexcom, she held various leadership roles at Johnson & Johnson Corporation from 2002 to 2023, including Worldwide Vice President, Immunology from 2017 to 2023 .
    Jacob S. LeachExecutive Vice President, Chief Operating OfficerAugust 2022Jacob S. Leach has served as the Executive Vice President and Chief Operating Officer of Dexcom since August 2022. Prior to this role, he was the Executive Vice President, Chief Technology Officer from October 2018 to August 2022. He has held various positions at Dexcom since joining in 2004 .
    Sadie M. SternExecutive Vice President, Chief Human Resources OfficerSeptember 2020Sadie M. Stern has served as the Executive Vice President and Chief Human Resources Officer at Dexcom since September 2020. Prior to joining Dexcom, she was employed by 3D Systems Corporation from October 2017 to September 2020, most recently as Executive Vice President, People and Culture .
    1. Despite your efforts to stabilize relationships with DME partners and become more channel agnostic, you're still losing some share; what concrete steps are you taking to regain lost DME share, and is it realistic to expect a return to your prior standing with DMEs in the near future?

    2. With the U.S. CGM market growth appearing to slow to around 10% in Q3, how confident are you in achieving your 2025 revenue target of $4.6 billion, and what specific strategies do you have in place to drive growth in a potentially slowing market?

    3. You mentioned a six-point impact from rebate dynamics on growth in Q3 and are expecting less impact in Q4; how will ongoing rebate pressures affect your pricing strategy and margins moving into 2025, and what actions are you taking to mitigate their impact on profitability?

    4. Given the uncertainty around the FDA approval timing for the 15-day G7 product, how are you incorporating potential delays into your 2025 financial projections, and what contingency plans do you have if the approval or rollout takes longer than anticipated?

    5. While you've reported record new patient starts this quarter, you've acknowledged that sales force productivity is still about three months behind; how will this lag affect your ability to meet your projected sequential growth in Q4 and adhere to your long-term guidance, and what specific measures are in place to accelerate productivity gains?

    Program DetailsProgram 1
    Approval DateJuly 25, 2024
    End Date/DurationJune 30, 2025
    Total additional amount$750.0 million
    Remaining authorization amount$0
    DetailsEnhance long-term value of share price; repurchases in open market or privately negotiated transactions
    YearAmount Due [Billions]Debt TypeInterest Rate [%]% of Total Debt
    20251.21 Senior Convertible Notes0.25 49.2% = (1.21 / 2.457.5) * 100
    20281.25 Senior Convertible Notes0.375 50.8% = (1.25 / 2.457.5) * 100

    Competitors mentioned in the company's latest 10K filing.

    • Abbott Laboratories; Medtronic plc’s Diabetes Group; Roche Diabetes Care, a division of Roche Diagnostics; LifeScan, Inc.; and Ascensia Diabetes Care - These companies manufacture and market products for the single-point finger stick device market and account for the majority of worldwide sales of self-monitored glucose testing systems .
    • Abbott - Competes with Dexcom's CGM systems with their Libre family of CGM products .
    • Medtronic - Markets and sells standalone glucose monitoring products called Guardian Connect and Simplera, and develops insulin pumps integrated with CGM systems .
    • Companies outside the traditional medical device sector - Attempting to develop competitive products and services, including for general health and wellness or population health .
    • Companies developing adjunctive CGMs - Compete with Dexcom's CGM products in the Medicare market following expanded Medicare coverage .
    NameStart DateEnd DateReason for Change
    Ernst & Young LLP2000 PresentCurrent auditor

    Recent developments and announcements about DXCM.

    Financial Reporting

      Earnings Report

      ·
      Jan 13, 2025, 12:56 PM

      DexCom, Inc. has released its preliminary, unaudited results for the fourth quarter and fiscal year 2024, along with its initial outlook for 2025. For the fourth quarter of 2024, Dexcom reported total revenue of at least $1.113 billion, marking an 8% increase over the same period in 2023. U.S. revenue is expected to be approximately $803 million, a 4% growth, while international revenue is projected at $310 million, a 17% increase over the fourth quarter of 2023.

      For the entire fiscal year 2024, the company anticipates total revenue of approximately $4.032 billion, which is an 11% increase from 2023. The company has updated its non-GAAP gross profit margin and operating margin guidance to 62% and 19% respectively for 2024. The fourth quarter gross margin was adversely affected by a non-cash charge related to inventory damage and production yield issues.

      Looking ahead to 2025, Dexcom expects total revenue to reach $4.60 billion, representing an anticipated growth of approximately 14% over 2024. This growth is expected to be driven by increased sensor volume, greater CGM access and awareness, the rollout of Stelo, and further international expansion. The company also projects a non-GAAP gross profit margin of approximately 64-65% and a non-GAAP operating margin of about 21% for 2025.

      Dexcom plans to report its audited full fourth quarter and fiscal 2024 financial results on February 13, 2025, after the market closes, with a conference call scheduled for 4:30 p.m. Eastern Time.

    Legal & Compliance

      Legal Proceedings

      ·
      Dec 23, 2024, 9:27 PM

      Summary of the Legal Matter Involving DexCom, Inc. and Abbott Diabetes Care, Inc.:

      • Key Parties Involved: The legal matter involves DexCom, Inc. (the 'Company') and Abbott Diabetes Care, Inc. ('Abbott') along with their respective affiliates.

      • Nature of the Proceedings: The proceedings were centered around global patent litigation where both parties accused each other of patent infringement. Each party also filed counterclaims and actions to invalidate the other party's patents.

      • Resolution: On December 20, 2024, DexCom and Abbott entered into a settlement and patent cross-license agreement to resolve all outstanding patent litigation between them. This agreement includes a worldwide, royalty-free, non-exclusive, fully paid-up license to certain patents and patent applications related to analyte sensing. Importantly, neither party is required to pay royalties or any other form of financial compensation.

      • Covenant Not to Sue: As part of the agreement, both parties have entered into a covenant not to sue each other until December 20, 2034, and have agreed not to challenge the licensed patents and patent applications for varying periods.

      • Potential Financial or Operational Consequences: The agreement eliminates the need for ongoing litigation expenses and potential financial liabilities related to patent infringement claims, allowing both companies to focus on their operations without the overhang of legal disputes .